Tynixa connects genomic variants, clinical context, evidence, draft ACMG logic, lab SOPs, human review, and audit trails into one commercial workflow.
Tynixa connects genomic variants, clinical context, evidence, draft ACMG logic, lab SOPs, human review, and audit trails into one commercial workflow.
The page should communicate the problem, the platform value, the workflow, the safety boundaries, and the next commercial step.
Every public page should include clear conversion paths without exposing internal pages.
The platform presents draft, evidence-bound workflows and does not provide final diagnosis or treatment.
Production language, left-to-right layout, full service coverage.
Production language, right-to-left layout, full service coverage.
Tynixa combines evidence extraction, ACMG draft automation, lab SOP logic, human review, audit trails, local variant memory, and self-hosted deployment into one safety-first interpretation workflow.
Book a pilot demo Explore demo cases
PubMed, ClinVar, population rarity, phenotype overlap, and lab policy are organized into traceable review cards.
Reviewer, senior reviewer, and lab director gates make sign-off explicit and auditable.
Deploy local-first with PHI controls, external LLM disabled by default, and audit packages for institutional review.
Transform variant evidence into consistent, reviewer-ready interpretation drafts.
Connect clinical context, phenotype evidence, and literature into a safe review process.
Support local deployment, local audit trails, and policy-controlled evidence workflows.